Fibrillin-1 (FBN1), a major structural component of microfibrils in extracellular matrix plays an important role in organ development and tissue homeostasis ([@bib51]; [@bib75]). Recent studies show that LTBP-1 (latent transforming growth factor-β binding protein-1) interacts with FBN1 through its pro-domains ([@bib7]; [@bib48]). Thus, *Fbn1* deficiency increases the level of activated TGF-β in the intercellular microenvironment. Clinically, *Fbn1* gene mutation is linked to several human diseases, including systemic sclerosis (SSc)/scleroderma, Marfan's syndrome, ectopic lentis, and the dominant form of Weill-Marchesani syndrome ([@bib34]; [@bib7]). These diseases are usually characterized by connective tissue fibrosis and skeletal disorders, but it is unclear whether *Fbn1* deficiency contributes to bone disorders in these diseases.

As an established SSc mouse model, *Fbn1* partial intragenic duplication mutant tight-skin mice (B6.Cg-*Fbn1^Tsk^*/J; *Fbn1^+/−^*) show significantly reduced femoral bone mineral density (BMD) and altered trabecular microarchitecture ([@bib5]). Loss of function of *Fbn1* induced a bone disorder involving elongated bone length and reduced bone density, similar to Marfan syndrome ([@bib10], [@bib11]; [@bib34]; [@bib47]), suggesting that dysregulation of TGF-β signaling by *Fbn1* mutation is the major factor underlying this bone deficiency ([@bib27]; [@bib12]; [@bib37]). *Fbn1^+/−^* mice represent an autoimmune connective tissue disorder characterized by type 2 helper T cell (T~H~2 cell) infiltration and vascular damage ([@bib17]). IL4, a key T~H~2 cytokine plays a critical role in the regulation of fibrotic tissue deposition through the signal transducer and activator of transcription-6 (STAT6) pathway ([@bib70]). Although the mechanism that results in an elevated level of IL4 in *Fbn1^+/−^* mice is unknown, down-regulation of the *Il4* gene in *Fbn1^+/−^* mice can rescue the pathogenesis in fibrotic diseases, suggesting that IL4 signaling is associated with fibrotic phenotype in SSc ([@bib31]). However, it is unknown whether IL4 signaling contributes to the osteoporotic phenotype in SSc mice.

BM mesenchymal stem cells (BMMSCs) constitute a population of self-renewal and multipotent cells that can differentiate into osteoblasts, adipocytes, fibroblasts, chondrocytes and nonmesenchymal cell types ([@bib14]; [@bib46]). BMMSCs are a promising cell source for bone regeneration and immunoregulatory therapies by interacting with several subsets of immune cells ([@bib33]; [@bib64]; [@bib49]; [@bib60]; [@bib63]; [@bib2]). In response to stimulation from multiple environmental factors, BMMSCs can differentiate into different lineage cells, which are regulated at both transcriptional and translational levels ([@bib55]; [@bib54]). In the present study, we show that *Fbn1* regulates BMMSC osteogenic/adipogenic lineage selection via IL4Rα/mTOR (the mammalian target of rapamycin) signaling. Blockage of the mTOR cascade by rapamycin, an anticancer and immune suppressive drug, ameliorates the osteopenia phenotype in *Fbn1^+/−^* SSc mice.

RESULTS
=======

*Fbn1* deficiency alters BMMSC lineage differentiation
------------------------------------------------------

Because *Fbn1* gene mutation leads to significant loss of bone volume and increase in BM adipocytes in B6.Cg-*Fbn1^Tsk^*/J (*Fbn1^+/−^*) mice ([@bib5]), we hypothesize that *Fbn1* deficiency may reduce osteogenic differentiation of BMMSCs and elevate their adipogenic differentiation. To test this hypothesis, we confirmed that *Fbn1* deficiency resulted in an osteopenia phenotype in *Fbn1^+/−^* mice. MicroCT and histological analysis showed that BMD, bone volume versus total volume (BV/TV), and distal femoral trabecular bone structure of *Fbn1^+/−^* mice were markedly decreased compared with the WT littermates ([Fig. 1, A--D](#fig1){ref-type="fig"}). Histomorphometric analysis revealed that the numbers of both osteoblasts and osteoclasts in the femur of *Fbn1^+/−^* mice were significantly reduced in comparison with the WT group by alkaline phosphatase (ALP) immunohistochemical (IHC) staining and tartrate-resistant acid phosphate (TRAP) staining, respectively ([Fig. 1, E and F](#fig1){ref-type="fig"}). The level of soluble receptor activator of nuclear factor κB ligand (sRANKL), but not osteoprotegerin (OPG), was significantly reduced ([Fig. 1, G and H](#fig1){ref-type="fig"}). In addition, we examined the in vivo function of osteoclasts and found that the serum type I collagen cross-linked telopeptide (CTX) level was significantly decreased in *Fbn1^+/−^* mice ([Fig. 1 I](#fig1){ref-type="fig"}). These data imply that the loss of bone volume in *Fbn1^+/−^* mice may be mainly associated with an insufficient bone formation. To examine whether *Fbn1* deficiency affects the stem cell properties of BMMSCs, we isolated BMMSCs ([Fig. 2, A--C](#fig2){ref-type="fig"}) to show that the number of colony forming unit-fibroblasts (CFU-Fs) was significantly reduced and the expression level of FBN1 was decreased in *Fbn1^+/−^* BMMSCs compared with the WT control ([Fig. 1, J and L](#fig1){ref-type="fig"}). The osteogenic differentiation capacity of *Fbn1^+/−^* BMMSCs was decreased, as indicated by reduced mineralized nodule formation and expression of the osteogenic regulators runt-related transcription factor 2 (RUNX2), ALP, and osteocalcin (OCN; [Fig. 1, K and L](#fig1){ref-type="fig"}). Using an established in vivo BMMSC implantation assay, in which 4 × 10^6^ BMMSCs with carrier hydroxyapatite tricalcium phosphate (HA/TCP) particles were subcutaneously implanted into immunocompromised mice, we showed that BMMSCs derived from *Fbn1^+/−^* mice generated less bone structure than the WT group at 8 wk after implantation ([Fig. 1 M](#fig1){ref-type="fig"}). To further confirm the role of *Fbn1* in BMMSC differentiation, we used siRNA to silence *Fbn1* gene expression in BMMSCs ([Fig. 2 D](#fig2){ref-type="fig"}) and found a significantly reduced osteogenic differentiation, as assessed by alizarin red staining to show reduced mineralized nodule formation, immunoblotting analysis to show decreased expression of the osteogenic markers RUNX2, ALP, and OCN, and in vivo BMMSC implantation assay to show reduction in new bone formation ([Fig. 1, N--P](#fig1){ref-type="fig"}). To further confirm reduced osteogenesis in *Fbn1^+/−^* mice, we performed a calcein labeling assay to show that the bone turnover rate was decreased in *Fbn1^+/−^* mice ([Fig. 1 Q](#fig1){ref-type="fig"}). In contrast, Oil red O staining showed the number of adipocytes in *Fbn1^+/−^* BM was markedly increased when compared with the WT littermates ([Fig. 2 E](#fig2){ref-type="fig"}). To confirm that *Fbn1* deficiency results in elevated adipogenesis, *Fbn1^+/−^* BMMSCs were found to exhibit a significantly elevated number of Oil red O--positive cells and up-regulation of the adipogenic regulators peroxisome proliferator-activated receptor γ2 (PPARγ2) and lipoprotein lipase (LPL) under adipogenic culture conditions ([Fig. 2, F and G](#fig2){ref-type="fig"}). Furthermore, we showed that *Fbn1*-silenced BMMSCs by siRNA had a significantly increased number of Oil red O--positive cells and up-regulation of PPARγ2 and LPL ([Fig. 2, H and I](#fig2){ref-type="fig"}). These data suggest that *Fbn1* governs osteogenic/adipogenic lineage differentiation in BMMSCs.

![***Fbn1*-deficient (*Fbn1^+/−^*) mice exhibit osteopenia phenotype.** (A--C) MicroCT (A), BMD (B), and BV/TV (C) analysis of trabecular bone (TB) area in WT and *Fbn1^+/−^* mouse distal femurs. (D) H&E staining of TB volume (yellow square) in distal femurs of *Fbn1^+/−^* mice (*n* = 15) and WT littermates (*n* = 10). Bar, 1 mm. (E) IHC staining of ALP^+^ osteoblasts in *Fbn1^+/−^* mice and WT littermates. (F) TRAP staining of osteoclasts in distal femur trabecular bone (TB) and BM in WT and *Fbn1^+/−^* mice. Arrowheads, TRAP^+^ osteoclasts (purple cells). Bar, 25 µm. (G--I) ELISA analysis of serum sRANKL (G), OPG (H), and CTX (I) in *Fbn1^+/−^* mice and WT littermates. (J) Toluidine blue staining showed the number of CFU-F from WT and *Fbn1^+/−^* BMMSCs. (K and N) Alizarin red staining of *Fbn1^+/−^* (K) and *Fbn1* siRNA knockdown (N) BMMSCs showed the capacity to form mineralized nodules when cultured under osteoinductive conditions. (L and O) Western blot analysis of *Fbn1^+/−^* (L) and *Fbn1* siRNA knockdown (O) BMMSCs showed expressed levels of FBN1 and the osteogenic genes RUNX2, ALP, and OCN. β-Actin was used as a protein loading control. (M and P) Subcutaneous implantation of BMMSCs in immunocompromised mice showed that bone (B), BM, and connective tissue (CT) were generated around HA/TCP (HA) at 8 wk after implantation. Bars, 50 µm. A semiquantitative analysis showed the amount of bone formation in BMMSC implants. (Q) Calcein double labeling of the metaphyseal trabecular bone in the distal femora showed the bone turnover rate in WT and *Fbn1^+/−^* mice. Bar, 25 µm. All experimental data verified in at least three independent experiments. Error bars represent the SD from the mean values. \*\*\*, P \< 0.005; NS, not significant.](JEM_20140643_Fig1){#fig1}

![***Fbn1*-deficient BMMSCs have increased adipogenic ability.** (A) Flow cytometric analysis showed the surface epitope profile of the isolated BMMSCs. (B and C) Alizarin red staining and Western blot showed the osteogenic differentiation capacities of BMMSCs derived from plastic collected single colonies, CD3 antibody/complement depletion, and flow cytometric sorting. (D) Western blot showed the efficacy of *Fbn1* siRNAs in BMMSCs. (E) Histological images of distal femurs showed the number of adipocytes in WT and *Fbn1^+/−^* mouse BM, as assessed by H&E and Oil red O staining. Bars, 50 µm. (F) The number of Oil red O^+^ cells in WT and *Fbn1^+/−^* BMMSCs under adipoinductive conditions. Bar, 50 µm. (G) Levels of adipogenic genes PPARγ2 and LPL in WT and *Fbn1^+/−^* BMMSCs under adipoinductive conditions. (H) The number of Oil red O^+^ cells in *Fbn1* siRNA knockdown BMMSCs. Bar, 50 µm. (I) Western blotting showed the expression levels of PPARγ2 and LPL in *Fbn1* siRNA knockdown BMMSCs. All experimental data verified in at least three independent experiments. Error bars represent the SD from the mean values. \*, P \< 0.05; \*\*, P \< 0.001.](JEM_20140643_Fig2){#fig2}

*Fbn1* modulates BMMSC lineage differentiation via IL4Rα/mTOR signaling
-----------------------------------------------------------------------

Because previous studies showed that *Fbn1* mutation induced T~H~2 infiltration with a high level of IL4 ([@bib17]), we used IHC staining and ELISA to confirm a higher number of IL4-positive cells in *Fbn1^+/−^* mouse BM and an elevated IL4 level in the peripheral blood ([Fig. 3, A and B](#fig3){ref-type="fig"}). In addition, we confirmed that *Fbn1^+/−^* mice showed significantly increased levels of T~H~2 cells ([Fig. 3, C-F](#fig3){ref-type="fig"}). Quantitative PCR and ELISA showed that WT and *Fbn1^+/−^* BMMSCs expressed similar low levels of IL4 ([Fig. 3, G and H](#fig3){ref-type="fig"}). Next, we examined whether activation of IL4 downstream signaling contributed to reduced osteogenesis and elevated adipogenesis in *Fbn1^+/−^* mice. We used immunofluorescence staining to confirm that BMMSCs coexpressed the MSC marker CD73 with IL4Rα ([Fig. 3 I](#fig3){ref-type="fig"}). Compared with control BMMSCs, *Fbn1^+/−^* BMMSCs show up-regulated expression of IL4Rα ([Fig. 3 J](#fig3){ref-type="fig"}), which was further confirmed by qPCR analysis ([Fig. 3 K](#fig3){ref-type="fig"}). Western blotting also showed that *Fbn1* deficiency up-regulated IL4Rα downstream signaling phosphoinositide 3-kinase (PI3K)--p110, phosphorylated Akt (p-Akt), and phosphorylated mTOR (p-mTOR) in *Fbn^+/−^* BMMSCs ([Fig. 3 J](#fig3){ref-type="fig"}). To verify that IL4Rα/mTOR signaling contributes to BMMSC osteo/adipo-lineage selection, we examined whether knockdown of the IL4Rα/mTOR cascade could rescue the altered lineage differentiation in *Fbn1^+/−^* BMMSCs. Having confirmed that shRNAs could knock down *Il4rα* and *mTOR* ([Fig. 3 L](#fig3){ref-type="fig"}) and that rapamycin treatment could inhibit mTOR signaling in a dose-dependent manner ([Fig. 3 M](#fig3){ref-type="fig"}), we showed that *Il4rα* and *mTOR* shRNAs, as well as rapamycin treatment, significantly improved osteogenic differentiation of *Fbn1^+/−^* BMMSCs, as indicated by alizarin red staining to show increased mineralized nodule formation, Western blotting to show elevated expression of the RUNX2, ALP, and OCN, and in vivo BMMSC implantation assay to show increased new bone formation at 8 wk after implantation ([Fig. 4, A--C](#fig4){ref-type="fig"}). Conversely, the elevated adipogenic differentiation in *Fbn1^+/−^* BMMSCs was significantly reduced in the shRNAs or rapamycin treatment groups, as indicated by a decreased number of Oil red O--positive cells and down-regulation of the PPARγ2 and LPL ([Fig. 4 D](#fig4){ref-type="fig"}). To avoid off-target effect, we used IL4Rα neutralizing antibody to block IL4 signaling and found decreased expression of p-mTOR and elevated expression of RUNX2 in *Fbn1^+/−^* BMMSCs when compared with control group ([Fig. 4 E](#fig4){ref-type="fig"}). We next revealed that mTOR regulated osteogenic differentiation of *Fbn1^+/−^* BMMSCs through its downstream signaling phosphorylated P70 ribosomal S6 protein kinase (P70S6K). Western blot analysis showed that p-P70S6K expression level was increased in *Fbn1^+/−^* BMMSCs ([Fig. 4 F](#fig4){ref-type="fig"}). When p-mTOR expression was knocked down by *Il4rα* and *mTOR* shRNAs, or rapamycin treatment, in *Fbn1^+/−^* BMMSCs, a corresponding down-regulation of p-mTOR and p-P70S6K was revealed by Western blot analysis ([Fig. 3 N](#fig3){ref-type="fig"}). Although knockdown of *P70s6k* expression by siRNA in *Fbn1^+/−^* BMMSCs resulted in up-regulation of RUNX2 expression ([Fig. 4 G](#fig4){ref-type="fig"}), the expression levels of mTOR was unaffected ([Fig. 4 H](#fig4){ref-type="fig"}). To avoid off-target effects, a second *P70s6k* siRNA was used to show elevated expression of RUNX2 ([Fig. 4 I](#fig4){ref-type="fig"}). In addition, the osteogenic differentiation was markedly increased in *P70s6k* knockdown *Fbn1^+/−^* BMMSCs, as indicated by elevated mineralized nodule formation ([Fig. 4 J](#fig4){ref-type="fig"}) and expression of the RUNX2, ALP, and OCN ([Fig. 4 K](#fig4){ref-type="fig"}). In contrast, the number of Oil red O--positive cells ([Fig. 4 L](#fig4){ref-type="fig"}) and the expression levels of the adipogenic genes were significantly down-regulated ([Fig. 4 M](#fig4){ref-type="fig"}), suggesting that mTOR regulates P70S6K to control RUNX2-mediated osteogenic differentiation and PPARγ2-mediated adipogenic differentiation.

![**T~H~2/IL4 infiltration in *Fbn1*-deficient mice.** (A) IHC staining of distal femoral in WT and *Fbn1^+/−^* mice showed the number of IL4^+^ cells (arrowheads) in BM. Bar, 25 µm. (B) ELISA showed the serum level of IL4 in WT and *Fbn1^+/−^* mice. (C--F) Flow cytometry showed T~H~2 subsets in peripheral blood (PB) and BM of WT and *Fbn1^+/−^* mice. (G and H) qPCR and ELISA analysis showed the levels of IL4 in WT and *Fbn1^+/−^* BMMSCs compared with T cells. (I) IF staining showed MSC marker CD73 coexpressed with IL4Rα in WT and *Fbn1^+/−^* BMMSCs. Bar, 25 µm. (J) Western blotting showed expression mTOR signaling genes, including IL4Rα, PI3K-p110, p-Akt, and p-mTOR in WT and *Fbn1^+/−^* BMMSCs. (K) qPCR analysis of IL4Rα in WT and *Fbn1^+/−^* BMMSCs. (L) Western blot showed efficacy of *Il4rα* and *mTOR* shRNAs in *Fbn1^+/−^* BMMSCs. (M) Western blot showed that rapamycin treatment induced a dose-dependent inhibition of p-P70S6K in *Fbn1^+/−^* BMMSCs. (N) Western blot showed the expression levels of p-mTOR and p-P70S6K in shRNAs and rapamycin-treated *Fbn1^+/−^* BMMSCs. Shown are representative of all experimental data verified in at least three independent experiments. Error bars represent the SD from the mean values. \*\*\*, P \< 0.005.](JEM_20140643_Fig3){#fig3}

![***Fbn1* deficiency-induced activation of IL4Rα/mTOR signaling regulates osteogenic/adipogenic lineage differentiation of BMMSCs.** (A) Alizarin red staining showed the capacity to form mineralized nodules in scrambled shRNA (sh-Scr)--treated, *Il4rα*, and *mTOR* shRNA- and rapamycin-treated *Fbn1^+/−^* BMMSCs. (B) Western blot showed the expression of the osteogenic genes RUNX2, ALP, and OCN in *Fbn1^+/−^* BMMSCs with shRNAs and rapamycin treatment. (C) H&E staining showed BMMSC-mediated bone (B) and BM regeneration when subcutaneously implanted into immunocompromised mice with *HA* carrier after shRNAs and rapamycin treatment in *Fbn1^+/−^* BMMSCs. Bars, 50 µm. A semiquantitative analysis showed the amount of bone formation in different implants. (D) Oil red O staining showed the capacity to differentiate into adipocytes in shRNAs and rapamycin-treated *Fbn1^+/−^* BMMSCs, as well as the expression levels of adipogenic genes PPARγ2 and LPL. Bar, 50 µm. (E) IL4Rα neutralizing antibody (NAb) treatment showed the expression levels of p-mTOR and RUNX2 in *Fbn1^+/−^* BMMSCs. (F) Western blot showed the level of p-P70S6K in *Fbn1^+/−^* BMMSCs. (G) Western blot showed the expression level of RUNX2 in *Fbn1^+/−^* BMMSCs after knockdown of *P70s6k* by siRNA. (H) Western blot analysis showed the expression of p-mTOR after knockdown of *P70s6k*. (I) To avoid off-target effects, two *P70s6k* siRNAs were used to show they both elevated expression of RUNX2 in *Fbn1^+/−^* BMMSCs. (J--M) Knockdown of *P70s6k* by siRNA, *Fbn1^+/−^* BMMSCs showed increased mineralized nodule formation by alizarin red staining (J), elevated expression of RUNX2, ALP, and OCN (K), decreased Oil red O^+^ cells (bar, 50 µm; L), and decreased expression of PPARγ2 and LPL (M). All experimental data verified in at least three independent experiments. Error bars represent the SD from the mean values. \*\*\*, P \< 0.005; \*\*, P \< 0.01.](JEM_20140643_Fig4){#fig4}

To further confirm that the IL4--IL4Rα pathway activates mTOR signaling, we performed a dosage and kinetics analysis to show that IL4 at a concentration of 50--100 ng/ml is able to activate mTOR signaling in WT BMMSCs and the activation of mTOR signaling can occur as earlier as 6 h after IL4 treatment ([Fig. 5, A and B](#fig5){ref-type="fig"}). When treated with IL4, *Fbn1^+/−^* BMMSCs exhibited a more significant increase in the expression of p-mTOR than the control BMMSCs ([Fig. 5 A](#fig5){ref-type="fig"}). Western blot analysis confirmed up-regulation of mTOR downstream signaling including PI3K, p-Akt, p-mTOR, and p-P70S6K ([Fig. 5 C](#fig5){ref-type="fig"}). Furthermore, we showed that IL4 treatment--activated mTOR signaling inhibited osteogenic differentiation of WT BMMSCs, as indicated by reduced mineralized nodule formation, decreased expression of the RUNX2, ALP, and OCN, and reduced bone formation when subcutaneously implanted into immunocompromised mice ([Fig. 5, D--F](#fig5){ref-type="fig"}), along with elevated adipogenic differentiation, as indicated by the increased number of Oil red O--positive cells and the expression of PPARγ2 and LPL ([Fig. 5, G and H](#fig5){ref-type="fig"}). These data suggest that activation of the IL4/IL4Rα/mTOR/P70S6K cascade contributes to osteogenic deficiency of *Fbn1^+/−^* BMMSCs and that blockade of mTOR signaling may be a promising therapeutic approach for rescuing osteogenic deficiency in *Fbn1^+/−^* mice.

![**IL4/mTOR signaling governs lineage commitment of BMMSCs.** (A) Western blot showed that IL4 treatment resulted in elevated expression of p-mTOR in an dose-dependent manner in WT and *Fbn1^+/−^* BMMSCs. (B) Western blot showed IL4 treatment resulted in elevated p-mTOR expression starting at 6 h after treatment and lasting until 72 h after treatment in WT BMMSCs. (C) Western blot showed the expression of mTOR signaling, including PI3K-p110, p-Akt, p-mTOR, and p-P70S6K in IL4-treated BMMSCs. (D) Alizarin red staining showed BMMSC-mediated mineralized nodule formation after mTOR activation. (E) Western blot indicated the expression of osteogenic genes RUNX2, ALP, and OCN in BMMSCs after mTOR activation. (F) H&E staining showed the capacity to form bone in mTOR-activated BMMSCs when implanted into immunocompromised mice. Bar, 50 µm. A semiquantitative analysis showed the amount of bone formation in implants. (G) Oil red O staining showed the number of adipocytes in mTOR-activated BMMSCs. Bar, 50 µm. (H) Western blot showed the expression of adipogenic genes PPARγ2 and LPL in mTOR-activated BMMSCs. (I) Western blot showed the expression levels of p-Rictor and p-Raptor in *Fbn^+/−^* BMMSCs. (J) Western blot showed the expression of osteogenic marker RUNX2 in *Fbn1^+/−^* BMMSCs after siRNA knockdown of either *Rictor* or *Raptor*. (K) Western blotting analysis showed that knockdown of *Rictor* resulted in down-regulation of both Raptor and Rictor, whereas knockdown of *Raptor* resulted in only down-regulation of Raptor. (L) To avoid off-target effects, second TORC1 or TORC2 siRNAs were used to show elevated expression of RUNX2 in BMMSCs. (M) Western blot showed that knockdown of Rictor, but not Raptor, resulted in down-regulation of p-Akt. All experimental data verified in at least three independent experiments. Error bars represent the SD from the mean values. \*\*\*, P \< 0.005.](JEM_20140643_Fig5){#fig5}

Because mTOR signaling involves two complexes, namely mTOR complex 1 (TORC1) and complex 2 (TORC2), we next examined which mTOR complex plays a functional role in regulating *Fbn1^+/−^* BMMSC differentiation. We found that *Fbn1^+/−^* BMMSCs expressed elevated levels of mTOR/Raptor/TORC1 and mTOR/Rictor/TORC2 when compared with the control group ([Fig. 5 I](#fig5){ref-type="fig"}). When using siRNA to knockdown either TORC1 or TORC2, the expression of the osteogenic marker Runx2 was up-regulated in *Fbn1^+/−^* BMMSCs ([Fig. 5 J](#fig5){ref-type="fig"}). Knockdown of TORC2 resulted in down-regulation of both Raptor and Rictor, whereas knockdown of TORC1 only resulted in down-regulation of Raptor ([Fig. 5 K](#fig5){ref-type="fig"}), suggesting that TORC2 may act upstream of TORC1. To avoid off-target effects, we used secondary TORC1 and TORC2 siRNAs to show they are able to elevate expression of RUNX2 in *Fbn1^+/−^* BMMSCs ([Fig. 5 L](#fig5){ref-type="fig"}). Because Akt is a downstream target of TORC2, we examined the expression levels of p-Akt after the knockdown of either TORC1 or TORC2 and confirmed that TORC2 acted upstream of TORC1 through the Akt cascade in *Fbn1^+/−^* BMMSCs ([Fig. 5 M](#fig5){ref-type="fig"}).

IL4Rα is activated by the TGF-β pathway in *Fbn1*-deficient BMMSCs
------------------------------------------------------------------

It was reported that FBN1 interacts with LTBP-1 to bind TGF-β ([@bib7]; [@bib48]). As such, *Fbn1* deficiency causes an increased release of TGF-β to the skin and lung ([@bib17]; [@bib23]). We examined the level of TGF-β in *Fbn1^+/−^* mouse BM and *Fbn1^+/−^* BMMSC culture medium and found that both BM and medium contained elevated levels of TGF-β, as assessed by ELISA assay ([Fig. 6 A](#fig6){ref-type="fig"}). Next, we used Western blotting to confirm that TGF-β downstream signaling p-SMAD3 and SMAD-associated transcription factor SP1 ([@bib13]; [@bib28]) were significantly increased in *Fbn1^+/−^* BMMSCs compared with the control BMMSCs ([Fig. 6 B](#fig6){ref-type="fig"}). To further confirm that *Fbn1* deficiency-mediated IL4Rα expression occurs through TGF-β release, we treated BMMSCs with recombinant TGF-β1 or *Fbn1* siRNA, followed by TGF-β neutralizing antibody blocking. Western blot analysis revealed that both TGF-β1 and *Fbn1* siRNA treatment increased IL4Rα levels, which could be blocked by TGF-β neutralizing antibody treatment ([Fig. 6, C--F](#fig6){ref-type="fig"}). To further confirm that TGF-β signaling activates IL4Rα expression, we used siRNA to block canonical TGF-β pathway and then examine the expression level of IL4Rα in *Fbn1^+/−^* BMMSCs. Western blot analysis showed that IL4Rα was significantly decreased in *Fbn1^+/−^* BMMSCs after *Smad2/3* siRNA treatment ([Fig. 6 G](#fig6){ref-type="fig"}), indicating that TGF-β/SMAD3 signaling may directly regulate IL4Rα expression. To determine whether increased expression of IL4Rα in *Fbn1^+/−^* BMMSCs is attributed to the TGF-β/SMAD3 signaling, we generated an *Il4rα* promoter reporter construct in which the defined region of the *Il4rα* promoter and flanking region were placed upstream of a reporter gene encoding firefly luciferase. We used BIOBASE biological databases to search the *Il4rα* promoter sequence and found two SP1 and one STAT6 candidate sites, which were closely matching with the SMAD3-associated SP1 and IL4Rα downstream STAT6 transcription factors consensus targets ([Fig. 6 H](#fig6){ref-type="fig"}). We next demonstrated that *Il4rα* promoter activity was markedly induced in both *Fbn1^+/−^* and TGF-β--treated BMMSCs. When *Fbn1^+/−^* BMMSCs were transfected with reporter vector, the luciferase assay showed a significantly increased *Il4rα* promoter activity. Introduction of SP1 mutated reporter vector markedly diminished the expression of the *Il4rα*-luciferase reporter in both *Fbn1^+/−^* and TGF-β--treated BMMSCs, indicating the direct initiation of IL4Rα expression by TGF-β--SMAD3--SP1 cascades ([Fig. 6 H](#fig6){ref-type="fig"}). We next determined whether SP1 regulates *Il4rα* promoter in BMMSCs. Using chromatin immunoprecipitation (ChIP), the SP1 binding consensus sequence within the promoter region was examined to confirm its ability to recruit SP1. As expected, SP1-bound DNA at the candidate site was significantly enriched in TGF-β--treated BMMSCs and *Fbn1^+/−^* BMMSCs ([Fig. 6 I](#fig6){ref-type="fig"}), suggesting that TGF-β may act as an initiator to elevate IL4Rα expression. In parallel, we used a ChIP-qPCR assay and found that STAT6 directly bound to the predicted promoter region of *Il4rα* and that STAT6 recruitment was enriched at the *Il4rα* promoter in *Fbn1^+/−^* or TGF-β--treated BMMSCs ([Fig. 6 I](#fig6){ref-type="fig"}). Western blot analysis further confirmed that an IL4Rα-JAK1-STAT6 cascade was activated in *Fbn1^+/−^* BMMSCs, as shown by up-regulation of p-JAK1 and p-STAT6 expression ([Fig. 6 J](#fig6){ref-type="fig"}). These results prompted us to examine whether STAT6 induced IL4Rα expression at the transcriptional level using a promoter reporter assay. Control BMMSCs, TGF-β--treated BMMSCs, and *Fbn1^+/−^* BMMSCs were transfected with a reporter vector or STAT6 candidate site mutated reporter vector, followed by luciferase assay. TGF-β--treated and *Fbn1^+/−^* BMMSCs showed increased promoter activity in comparison to control BMMSCs. Introduction of STAT6 mutated reporter vector markedly diminished the expression of the *Il4rα*-luciferase reporter in *Fbn1^+/−^* BMMSCs, but not TGF-β--treated BMMSCs. Thus, TGF-β may act as an initiator to elevate IL4Rα expression, and TGF-β--activated IL4Rα is independent from IL4Rα-STAT6 cascades ([Fig. 6 H](#fig6){ref-type="fig"}). These results prompted us to examine whether TGF-β and IL4 synergistically activate the mTOR signaling in BMMSCs. We found that TGF-β, but not IL4, treatment elevated the expression levels of IL4Rα in BMMSCs by Western blot analysis ([Fig. 6, K and L](#fig6){ref-type="fig"}). Although TGF-β and IL4 treatments each elevated expression levels of p-mTOR in BMMSCs, combinatorial treatment of TGF-β and IL4 resulted in a marked increase in p-mTOR expression ([Fig. 6, K and L](#fig6){ref-type="fig"}). These results indicate that the *Fbn1* deficiency-induced TGF-β--SMAD3--SP1/IL4Rα cascade synergistically enhances mTOR signaling with STAT6 signaling in *Fbn1^+/−^* BMMSCs at the transcriptional level, which leads to lineage alteration of *Fbn1^+/−^* BMMSC.

![**TGF-β and STAT6 synergistically enhance the expression of IL4Rα in *Fbn^+/−^* BMMSCs.** (A) ELISA assay showed the level of TGF-β in *Fbn1^+/−^* mouse serum and *Fbn1^+/−^* BMMSCs cultured medium compared with WT group. (B) Western blotting showed the expression levels of p-SMAD3 and SP-1 in WT and *Fbn1^+/−^* BMMSCs. (C and D) Western blotting showed that TGF-β treatment elevated IL4Rα expression in BMMSCs, which could be blocked by TGF-β neutralizing antibody (NAb). (E and F) Western blot showed that *Fbn1* knockdown by siRNA in BMMSCs elevated IL4Rα expression, which could be blocked by TGF-β NAb. (G) Western blot showed the expression of IL4Rα after *Smad2/3* siRNA treatment compared with vehicle-treated group. (H) *Il4rα* promoter luciferase fusions were examined in WT, TGF-β--treated, and *Fbn1^+/−^* BMMSCs. Promoter activity was expressed as relative light units (RLU) normalized to the activity of cotransfected Renilla luciferase. (I) ChIP-qPCR assay showed enrichment of direct association of SP1 and STAT6 on *Il4rα* promoter in TGF-β--treated and *Fbn1^+/−^* BMMSCs. (J) Western blot showed the expression of p-JAK1 and p-STAT6 in *Fbn1^+/−^* BMMSCs. (K and L) Western blotting showed the expression of IL4Rα and p-mTOR after TGF-β, IL4, or combinatorial treatment with TGF-β and IL4. All experimental data verified in at least three independent experiments. Error bars represent the SD from the mean values. \*\*\*, P \< 0.005.](JEM_20140643_Fig6){#fig6}

Conditional knockdown of IL4Rα/mTOR in BMMSCs/osteoblasts or rapamycin treatment ameliorates osteopenia phenotype in *Fbn1^+/−^* mice
-------------------------------------------------------------------------------------------------------------------------------------

Because IL4Rα/mTOR alters BMMSC lineage commitment, depletion of mTOR expression in BMMSC lineage may serve as a key approach to recover *Fbn1* deficiency-induced osteopenia. To achieve such a tissue-specific KO, we first generated *Prrx1-Cre;Il4rα^f/-^;Fbn1^+/−^* triple conditional KO (TKO) mice to KO IL4Rα in *Fbn1^+/−^* BMMSCs ([Fig. 7 A](#fig7){ref-type="fig"}). *Il4rα^f/−^* littermates were used as normal control, and *Il4rα^f/−^;Fbn1^+/−^* (DKO) littermates were used as osteopenia models ([Fig. 7 A](#fig7){ref-type="fig"}). The efficacy of *Cre*-medicated deletion of floxed alleles was shown by qPCR analysis ([Fig. 7 B](#fig7){ref-type="fig"}). MicroCT analysis showed that TKO mice have significantly increased BMD compared with DKO mice, indicating that *Il4rα* conditional KO rescued BMD in *Fbn1* deficiency--induced osteopenia ([Fig. 7 C](#fig7){ref-type="fig"}). Histological analysis showed that trabecular bone volume in TKO mice was increased compared with the DKO mice ([Fig. 7 D](#fig7){ref-type="fig"}). The numbers of adipocytes in TKO mouse BM were significantly reduced when compared with the DKO mice, as assessed by Oil red O staining ([Fig. 7 D](#fig7){ref-type="fig"}). To investigate the role of IL4Rα in the differentiation of *Fbn1^+/−^* BMMSCs, we isolated BMMSCs from DKO mice and knocked down *Il4rα* using an adenovirus expressing *Cre* with GFP (Ad-Cre-DKO-BMMSCs) or an adenovirus expressing GFP only (Ad-GFP-DKO-BMMSCs) as a control. Ad-Cre-DKO-BMMSCs showed significantly increased osteogenic differentiation, as assessed by alizarin red staining indicating elevated mineralized nodule formation ([Fig. 7 E](#fig7){ref-type="fig"}); Western blotting indicating rescued expression of the mTOR/osteogenic cascade genes p-mTOR, RUNX2, ALP, and OCN ([Fig. 7 F](#fig7){ref-type="fig"}); and in vivo implantation indicating elevated bone formation capacity compared with the Ad-GFP-DKO-BMMSCs ([Fig. 7 H](#fig7){ref-type="fig"}). To avoid off-target effect, we used IL4Rα neutralizing antibody to block IL4 signaling and found elevated expression of RUNX2 in DKO BMMSCs ([Fig. 7 G](#fig7){ref-type="fig"}). In contrast, Ad-Cre-DKO-BMMSCs showed a significant decrease in adipogenic differentiation compared with Ad-GFP-DKO-BMMSCs, as shown by a decreased number of Oil red O--positive cells and down-regulation of the adipogenic genes PPARγ2 and LPL ([Fig. 7, I and J](#fig7){ref-type="fig"}).

![**Conditional KO of IL4Rα in BMMSC ameliorates osteopenia phenotype by rescuing impaired osteogenic/adipogenic differentiation.** (A) Experimental outline describing the use of *Il4rα^f/f^* crossed with *Fbn1^+/−^* mice to generate *Il4rα^f/+^*;*Fbn1^+/−^* mice. *Prrx1*-*Cre* mice were crossed with *Il4rα^−/−^* mice to generate *Prrx1-Cre;Il4rα^+/−^* mice. *Il4rα^f/+^*;*Fbn1^+/−^* mice were then crossed with *Prrx1-Cre;Il4rα^+/−^* mice to generate *Il4rα^f/-^*;*Fbn1^+/−^* (DKO, *n* = 9) and *Prrx1-Cre;Il4rα^f/-^*;*Fbn1^+/−^* (TKO, *n* = 7) conditional KO mice. *Il4rα ^f/−^* littermates (*n* = 15) were used as control. (B) qPCR analysis showed the efficacy of *Cre*-medicated deletion of the floxed allele. (C) MicroCT analysis showed the BMD of DKO and TKO mice. Bar, 1 mm. (D) H&E (bar, 1 mm) and Oil red O (bar, 50 µm) staining showed the *TB* volume and percentage of adipocytes in distal femur. (E) Alizarin red staining showed the mineralized nodule forming capacity in Adenovirus-Cre--treated BMMSCs derived from DKO mice (Ad-Cre) compared with Adenovirus-GFP--treated DKO group (Ad-GFP). (F) Western blot analysis showed the expression of p-mTOR, RUNX2, ALP, and OCN in Ad-Cre compared with Ad-GFP. (G) Western blot showed the expression of RUNX2 in IL4Rα NAb-treated DKO BMMSCs. (H) When implanted into immunocompromised mice subcutaneously with *HA* carrier, Ad-Cre showed significantly increased bone formation. Bar, 50 µm. (I) Oil red O staining showed the number of adipocytes in Ad-Cre. Bar, 50 µm. (J) Western blotting showed the expression of adipogenic genes PPARγ2 and LPL in Ad-Cre. All experimental data verified in at least three independent experiments. Error bars represent the SD from the mean values. \*\*\*, P \< 0.005.](JEM_20140643_Fig7){#fig7}

We next generated *Prrx1-Cre;Mtor^f/+^;Fbn1^+/−^* TKO mice to KO mTOR in *Fbn1^+/−^* BMMSCs ([Fig. 8 A](#fig8){ref-type="fig"}). *Mtor^f/+^* littermates were used as normal control, and *Mtor^f/+^;Fbn1^+/−^* (DKO) littermates were used as osteopenia models ([Fig. 8 A](#fig8){ref-type="fig"}). The efficacy of *Cre*-medicated deletion of floxed allele was shown by qPCR analysis ([Fig. 8 B](#fig8){ref-type="fig"}). MicroCT analysis showed that *Mtor* conditional KO rescued BMD in *Fbn1* deficiency--induced osteopenia ([Fig. 8 C](#fig8){ref-type="fig"}). Histological analysis showed that trabecular bone volume in TKO mice was increased compared with the DKO mice ([Fig. 8 D](#fig8){ref-type="fig"}). The numbers of adipocytes in TKO mouse BM were significantly reduced when compared with the DKO mice, as assessed by Oil red O staining ([Fig. 8 D](#fig8){ref-type="fig"}). To investigate the role of mTOR in the differentiation of *Fbn1* deficient BMMSCs, we isolated BMMSCs from DKO mice and knocked down *Mtor* using an adenovirus expressing *Cre* with GFP or an adenovirus expressing GFP only as a control. Ad-Cre-DKO-BMMSCs showed significantly increased osteogenic differentiation, as assessed by alizarin red staining indicating elevated mineralized nodule formation ([Fig. 8 E](#fig8){ref-type="fig"}); Western blot analysis indicating rescued expression of the osteogenic cascade genes RUNX2, ALP, and OCN ([Fig. 8 F](#fig8){ref-type="fig"}); and in vivo implantation indicating elevated bone formation capacity compared with the Ad-GFP-DKO-BMMSCs ([Fig. 8 G](#fig8){ref-type="fig"}). In contrast, Ad-Cre-DKO-BMMSCs showed a significant decrease in adipogenic differentiation compared with Ad-GFP-DKO-BMMSCs, as shown by a decreased number of Oil red O--positive cells and down-regulation of the adipogenic genes PPARγ2 and LPL ([Fig. 8, H and I](#fig8){ref-type="fig"}).

![**Conditional KO of mTOR in BMMSC ameliorates osteopenia phenotype by rescuing impaired osteogenic/adipogenic differentiation.** (A) Experimental outline describing the generation of *Mtor^f/+^*;*Fbn1^+/−^* (DKO, *n* = 8) and *Prrx1-Cre;Mtor^f/+^;Fbn1^+/−^* (TKO, *n* = 6) mice. (B) qPCR analysis showed the efficacy of *Cre*-medicated deletion of the floxed allele. (C) MicroCT analysis showed the BMD of DKO and TKO mice. Bar, 1 mm. (D) H&E (bar, 1 mm) and Oil red O (bar, 50 µm) staining showed the TB volume and adipocytes in distal femur of DKO and TKO mice. (E) Alizarin red staining showed the mineralized nodule formation in Ad-Cre. (F) Western blotting showed the expression levels of p-mTOR, RUNX2, ALP, and OCN in Ad-Cre and Ad-GFP. (G) When implanted into immunocompromised mice with *HA* carrier, Ad-Cre showed significantly increased bone formation. Bar, 50 µm. (H) Quantitative analysis showed the number of Oil red O^+^ cells in Ad-Cre. Bar, 50 µm. (I) Western blotting showed the expression of adipogenic genes PPARγ2 and LPL in Ad-Cre compared with Ad-GFP. All experimental data verified in at least three independent experiments. Error bars represent the SD from the mean values. \*\*\*, P \< 0.005.](JEM_20140643R_Fig8){#fig8}

It has been shown that SP7-expressing osteoblastic progenitors have the ability to control osteoblastic/adipogenic lineage switch ([@bib77]; [@bib58]). To examine whether knocking down mTOR signaling in the preosteoblastic stage can recover the lineage alteration and osteopenia phenotype in *Fbn1^+/−^* mice, we generated a tissue-specific KO, *SP7-Cre*;*Mtor^f/+^;Fbn1^+/−^* (TKO) conditional *Mtor* KO mice ([Fig. 9 A](#fig9){ref-type="fig"}). Floxed *Mtor* littermates (*Mtor^f/+^*) were used as normal control and *Mtor^f/+^;Fbn1^+/−^* (DKO) littermates were used as osteopenia models ([Fig. 9 A](#fig9){ref-type="fig"}). The efficacy of *Cre*-medicated deletion of floxed allele was shown by qPCR analysis ([Fig. 9 B](#fig9){ref-type="fig"}). MicroCT analysis and histological analyses showed that TKO mice have significantly increased BMD and trabecular bone volume compared with DKO mice ([Fig. 9 C](#fig9){ref-type="fig"}), suggesting that *Mtor* conditional KO in the preosteoblastic lineage rescued osteopenia in *Fbn1*-deficient mice. The number of adipocytes in TKO mouse BM was significantly reduced when compared with the DKO mice, as assessed by Oil red O staining ([Fig. 9 C](#fig9){ref-type="fig"}). These data prompted us to use a drug, specifically rapamycin, to attempt to ameliorate the disease phenotype in *Fbn1^+/−^* mice.

![**Conditional KO of mTOR in preosteoblastic lineage ameliorates osteopenia phenotype.** (A) Experimental outline describing the generation of *Mtor^f/+^*;*Fbn1^+/−^* (DKO, *n* = 6) and *Sp7-Cre*;*Mtor^f/+^*;*Fbn1^+/−^* (TKO, *n* = 6) mice. (B) qPCR analysis showed the efficacy of *Cre*-medicated deletion of the floxed allele. (C) MicroCT (bar, 1 mm), H&E (bar, 1 mm), and Oil red O (bar, 50 µm) staining showed BMD, TB volume, and the number of adipocytes in distal femur of DKO and TKO mice. All experimental data verified in at least three independent experiments. Error bars represent the SD from the mean values. \*\*\*, P \< 0.005.](JEM_20140643R_Fig9){#fig9}

Next, we examined whether rapamycin treatment rescued the osteopenia phenotype in *Fbn1^+/−^* mice. Rapamycin was intraperitoneally administered to *Fbn1^+/−^* mice at 8 or 6 wk of age for 14 or 28 consecutive days, respectively. The samples were harvested at 10 wk of age for further evaluation ([Fig. 10 A](#fig10){ref-type="fig"}). Histological and microCT analysis showed that rapamycin treatment elevated BMD and trabecular bone volume in *Fbn1^+/−^* mice ([Fig. 10 B](#fig10){ref-type="fig"}). The number of adipocytes in BM of rapamycin-treated *Fbn1^+/−^* mice was significantly reduced when compared with untreated *Fbn1^+/−^* mouse BM, as assessed by Oil red O staining ([Fig. 10 B](#fig10){ref-type="fig"}). BMMSCs isolated from rapamycin-treated *Fbn1^+/−^* mice showed significantly increased CFU-F number compared with the untreated group ([Fig. 10 C](#fig10){ref-type="fig"}). Osteogenic differentiation of BMMSCs from rapamycin-treated *Fbn1^+/−^* mice was markedly improved when compared with the untreated *Fbn1^+/−^* BMMSCs, as analyzed by alizarin red staining to show elevated mineralized nodule formation and Western blot analysis to show decreased expression of p-mTOR and p-P70S6K and increased expression of the RUNX2, ALP, and OCN ([Fig. 10, D and E](#fig10){ref-type="fig"}). In contrast, BMMSCs isolated from rapamycin-treated *Fbn1^+/−^* mice showed a significant decrease in adipogenic differentiation compared with the untreated *Fbn1^+/−^* BMMSCs, as shown by decreased number of Oil red O--positive cells and down-regulation of the PPARγ2 and LPL ([Fig. 10, F and G](#fig10){ref-type="fig"}).

![**Rapamycin treatment ameliorates osteopenia phenotype by rescuing impaired osteogenic/adipogenic differentiation of BMMSCs in *Fbn1^+/−^* mice.** (A) Experimental outline describing the use of rapamycin to treat *Fbn1^+/−^* mice (*n* = 6 per group). (B) MicroCT, H&E (bar, 1 mm), and Oil red O (bar, 50 µm) staining showed BMD, TB volume, and adipocytes in distal femur of *Fbn1^+/−^* mice after rapamycin treatment. (C) CFU-F number of BMMSCs isolated from rapa-treated *Fbn1^+/−^* mice compared with *Fbn1^+/−^* mice. (D) Alizarin red staining showed the mineralized nodule forming capacity in BMMSCs from rapa-treated *Fbn^+/−^* mice. (E) Western blot showed the expression levels of p-mTOR, p-P70S6K, RUNX2, ALP, and OCN in BMMSCs from rapa-treated *Fbn1^+/−^* mice. (F) Oil red O staining showed the number of adipocytes in rapa-treated *Fbn1^+/−^* BMMSCs. Bar, 50 μm. (G) Western blot showed the expression levels of PPARγ2 and LPL in rapa-treated *Fbn1^+/−^*BMMSCs. All experimental data verified in at least three independent experiments. Error bars represent the SD from the mean values. \*\*\*, P \< 0.005.](JEM_20140643_Fig10){#fig10}

DISCUSSION
==========

FBN1 is essential for the formation of elastic fibers or microfibrils that provide strength and flexibility to connective tissue. Normally, FBN1 is abundant in the connective tissue of the aorta, ligature of the human eye lens, bones, and lungs. Mutation of the fibrillin gene causes SSc and Marfan's syndrome, in which bone and connective tissue disorders are observed. The bone defects in SSc patients were considered to be an insignificant clinical symptom; however, recent emerging evidence shows that bone resorption may be a common clinical manifestation ([@bib4]; [@bib29]; [@bib44]). In the present study, we identified a marked osteopenia phenotype in *Fbn1* mutant-induced SSc mice. Recently, it was suggested that FBN1 and FBN2 might differentially regulate endogenous BMP and TGF-β activity in osteoblasts to affect bone growth and development ([@bib43]). In this study, we reveal that *Fbn1* deficiency results in an increased level of TGF-β in BM, which, in turn, initiates a cascade in which IL4Rα is up-regulated in BMMSCs via SMAD3/SP1 binding to *Il4rα* promoter, leading, as a consequence, to the activation of mTOR-P70S6K signaling to directly suppress osteogenesis via RUNX2 and promote adipogenesis via PPARγ2, respectively. Osteogenic differentiation deficiency in *Fbn1^+/−^* BMMSCs may contribute to an osteoporotic phenotype, such as low BMD or reduced trabecular bone structure, in *Fbn1^+/−^* SSc mice. However, inhibition of mTOR signaling using rapamycin treatment appears to be a promising approach to rescue osteoporotic disorders in the SSc mice.

It is known that mTOR signaling positively regulates expression of the adipogenic gene PPARγ2, which is critical for adipogenesis of BMMSCs ([@bib30]; [@bib74]; [@bib76]). However, controversial findings were reported regarding mTOR signaling in osteogenesis in that mTOR may be required for osteoblast proliferation, which is involved in several signaling pathways through IL6 ([@bib32]; [@bib61]; [@bib62]). In contrast, rapamycin may either inhibit ([@bib56]) or stimulate ([@bib36]; [@bib41]) osteogenesis, depending on cell type or differentiation stages. Recently, it has been reported that bone matrix secretes IGF-1 (insulin-like growth factor-1) to recruit normal BMMSCs for bone remodeling by activating mTOR signaling ([@bib71]), indicating that mTOR may contribute to the activation of different sets of biological regulatory controls under certain conditions. In this study, we reveal that elevated IL4Rα expression leads to the activation of mTOR-P70S6K signaling in *Fbn1^+/−^* BMMSCs, which directly inhibits the osteogenic gene RUNX2 and suppresses bone regeneration in vitro and in vivo. In contrast, rapamycin represses mTOR/P70S6K signaling, which results in rescuing BMMSC deficiency and ameliorating the osteoporotic phenotype in *Fbn1^+/−^* mice, implicating that IL4Rα/mTOR is, in fact, a major signaling pathway contributing to the osteopenia phenotype in *Fbn1^+/−^* mice. mTORC1 controls multiple cellular regulation processes, such as protein synthesis, cell proliferation, metabolism, and autophagy ([@bib25]). It is possible that activation of the mTORC1 pathway increases biosynthetic activity to improve osteogenesis rather than decrease bone formation. Thus, the mechanistic details may not totally explain the phenotype and further study is required to explore the detailed relationship between the mechanism and the phenotype. Because *Fbn1^−/−^* mice are embryonic lethal, we cannot examine whether *Fbn1* null shows a phenotype similar to that observed in *Fbn1*-deficient conditions.

T~H~2 cells are a major source of IL4 production in SSc ([@bib31]; [@bib17]). *Fbn1^+/−^* mice show T~H~2 infiltration and high levels of IL4. Disruption of IL4 can rescue the fibrotic phenotype, suggesting that a high level of IL4 may also play a critical role in the disease pathogenesis ([@bib31]; [@bib70]; [@bib17]). Recent studies show that TGF-β contributes to the fibrotic phenotype in SSc through activation of extracellular matrix protein expression, suggesting that TGF-β and IL4 signaling may synergistically activate downstream targets to induce fibrosis in SSc ([@bib65]; [@bib17]; [@bib18]). Although overproduction of IL4 can induce osteoporotic phenotype in mice ([@bib38]), activation of IL4Rα may inhibit osteoblast proliferation ([@bib15]), indicating that IL4 may affect BMMSC function. Conversely, it was reported that local delivery of IL4, using a gene therapy approach, prevented bone erosion in arthritis animal models via abrogation of osteoclastogenesis ([@bib40]; [@bib69]; [@bib50]). These findings indicate that elevated IL4 caused by *Fbn1* deficiency may contribute to a low osteoblast/osteoclast turnover rate, as observed in *Fbn1^+/−^* mice. It was reported that TGF-β stimulates osteoclastogenesis via the TAK1--NF-κB pathway ([@bib42]; [@bib20]). IL4 is a potent inhibitor of osteoclastogenesis that operates through various mechanisms, such as rapid suppression of NFATc1 expression ([@bib67]; [@bib9]) and reduction of RANKL expression ([@bib16]) via activation of the STAT6 pathway. Our results showed that *Prrx1*-*Cre*--mediated knockdown of IL4Rα rescued the osteopenia phenotype and altered BMMSC lineage differentiation in *Fbn1^+/−^* mice; however, elevated serum TGF-β levels were unchanged. Therefore, IL4 signaling may play a critical role in determining osteoclastogenesis in *Fbn1^+/−^* mice. Our data also suggest that IL4/IL4Rα signaling activates mTOR signaling in *Fbn1^+/−^* BMMSCs, which alters BMMSC osteogenic/adipogenic lineage differentiation, as a consequence of reduced osteogenesis and elevated adipogenesis in BM.

The lineage switch between osteoblasts and adipocytes may be regulated by multiple mechanisms, including at least IL4R/mTOR signaling at the early BMMSC (*Prrx1*-*Cre*) and osteoblastic progenitor stages (*SP7*-*Cre*). Previous studies showed that SP7-expressing osteoblastic progenitors have the ability to control the osteoblastic/adipogenic lineage switch ([@bib77]; [@bib58]) and that SP7 can be regulated by small microRNA ([@bib77]). Our data showed that *SP7*-*Cre*--mediated KO of IL4Rα/mTOR cascades can rescue the BMMSC lineage alteration and osteopenia phenotype in *Fbn1^+/−^* mice. These data may encourage us to use a drug such as rapamycin to ameliorate the disease phenotype in *Fbn1^+/−^* mice. Rapamycin, a specific mTOR inhibitor, is a novel nonsteroidal anticancer and immunosuppressive drug ([@bib1]; [@bib66]; [@bib53]). Several preclinical studies showed that rapamycin is effective in treating autoimmune diseases, such as systemic lupus erythematosus and rheumatoid arthritis ([@bib72]; [@bib26]). These diseases are usually associated with bone disorders ([@bib68]). Although efficacy of rapamycin treatment in SSc patients must be assessed in clinical studies, phase I clinical trials showed optimal safety for its use in treating scleroderma patients ([@bib59]). Added experimental evidence showed that rapamycin treatment resulted in a significant improvement of skin phenotype with regulation of immune index, such as reducing the levels of IL4 and IL17 in *Fbn1^+/−^* mice ([@bib73]). These data suggest that the underlying mechanism of rapamycin-mediated treatment may be associated with immunomodulation, leading to the down-regulation of T~H~2 cells ([@bib35]). Up-regulation of osteogenesis and down-regulation of adipogenesis in rapamycin-treated *Fbn1^+/−^* mice via inhibition of mTOR signaling in BMMSCs may help to rebuild functional osteoblasts to improve niche microenvironment for immune cells and rebuild homeostasis for the immune system. Because of the extensive functional roles of rapamycin in immune, anticancer, and osteoporosis therapies, it is necessary to explore detailed mechanisms by which rapamycin may target several signaling pathways simultaneously.

MATERIALS AND METHODS
=====================

### Animals.

Female C57BL/6J, B6.Cg-*Fbn1^Tsk^*/J, B6.Cg-Tg(Prrx1-cre)1Cjt/J, B6.Cg-Tg (*Sp7*-tTA, tetO-EGFP/cre)1Amc/J, and B6.129S4-*Mtor^tm1.2koz^*/J mice were purchased from The Jackson Laboratory and maintained in C57BL/6J background in at least 10 backcrosses. Age-matched female littermates were used in all experiments. Female immunocompromised nude mice (Beige *nu/nu* XIDIII) were purchased from Harlan. IL4Rα null (*Il4rα^−/−^*) and floxed (*Il4rα^ϕ/ϕ^*; [@bib22]) mice were gifts from F. Brombacher (University of Cape Town, Cape Town, South Africa). To generate tissue-specific Cre-mediated KO models, *Cre*-, floxed-, and *Fbn1^+/−^* mice were intercrossed, and age-matched female littermates were used as WT controls. All animal experiments were performed under the institutionally approved protocols for the use of animal research (University of Southern California protocol numbers 11141, 11953, and 11327).

### MicroCT analysis.

Femurs were harvested and analyzed by Inveon micro-CT system (Siemens AG). Cross-sectional volumetric BMD was measured at right femur mid-diaphysis with a density phantom. Using 3-dimensional images, a region of interest in secondary spongiosa was manually drawn near the endocortical surface, and BV/TV was assessed as a cancellous bone morphometric parameter.

### In vivo BMMSC implantation assay.

Approximately 4.0 × 10^6^ BMMSCs were mixed with HA/TCP ceramic powders (40 mg; Zimmer Inc.) and subcutaneously implanted into 8-wk-old immunocompromised mice ([@bib21]). At 8 wk after implantation, the transplants were harvested, fixed in 4% PFA, and decalcified with 5% EDTA, pH 7.4, followed by paraffin embedding. The 6-µm paraffin sections were stained with H&E chemical staining. Total BV/TV was quantified by ImageJ software (National Institutes of Health).

### In vivo Oil red O staining.

To assess the adipose tissue in trabecular areas, femurs were fixed in 4% paraformaldehyde and decalcified with 5% EDTA, pH 7.4, followed by cryosection. Sections were stained with Oil Red O, and positive areas were quantified under microscopy and shown as a percentage of total areas.

### In vivo rapamycin treatment.

Rapamycin (LC Laboratories) was in the vehicle containing 0.2% sodium carboxymethylcellulose (Sigma-Aldrich) and 0.25% polysorbate 80 (Sigma-Aldrich). Rapamycin with vehicle was intraperitoneally administered to *Fbn1*-deficient mice at a dose of 1.5 mg/kg/d for 14 and 28 d, respectively ([@bib6]). The disease group and control mice were treated with vehicle only. Treatment was started at age 6 or 8 wk, and all groups of mice were healthy.

### Histology.

To assess trabecular bone and BM areas, femurs were fixed in 4% paraformaldehyde (Sigma-Aldrich) and then decalcified with 5% EDTA, pH 7.4, followed by paraffin embedding. Paraffin sections (6 µm) were stained with hematoxylin and eosin (H&E) and analyzed by ImageJ software. To perform immunohistochemistry staining, the paraffin-embedded sections were blocked with serum matched to secondary antibodies, incubated with the ALP or IL4 specific antibodies (1:400; Santa Cruz Biotechnology, Inc.) at 4°C for overnight, and then stained using VECTASTAIN UNIVERSAL elite ABC kit and ImmPACT VIP Peroxidase Substrate kit (Vector Laboratories) according to the manufacturer's instruction. To quantify osteoclast activity, mature osteoclasts were determined by TRAP-positive cells on the bone surface. Deparaffinized sections were refixed with a mixture of 50% ethanol and 50% acetone for 10 min. TRAP staining solutions (1.6% naphthol AS-BI phosphate in *N*, *N*-dimethylformamide, 0.14% fast red-violet LB diazonium salt, 0.097% tartaric acid, and 0.04% MgCl~2~ in 0.2 M sodium acetate buffer at pH 5.0) were freshly made. The sections were incubated in the solution for 10 min at 37°C under shield and counterstained with toluidine blue. All reagents for TRAP staining were purchased from Sigma-Aldrich. To label the mineralization fronts, the mice were given subcutaneous injections of calcein (15 mg/kg body weight; Sigma-Aldrich) in 2% sodium bicarbonate solution 10 and 3 d before sacrifice. Bone dynamic histomorphometric analyses for MAR, MS/BS, and BFR/BS were performed according to the standardized nomenclature for bone histomorphometry ([@bib45]).

### ELISA.

Peripheral blood serum and cell culture medium were collected, and sRANKL, OPG, IL4, and TGF-β protein levels were analyzed using mouse ELISA Ready-SET-GO kits (eBioscience), according to the manufacturer's instructions. CTX levels were analyzed with a mouse C-telopeptide of type I collagen ELISA kit (Novateinbio), according to the manufacturer's instructions. Human IL4 and TGF-β protein levels were analyzed using ELISA Ready-SET-GO kits (eBioscience), according to the manufacturer's instructions. Human sRANKL protein levels were analyzed using sRANKL Super X ELISA kit (Antigenix America Inc.) and OPG levels were analyzed by OPG instant ELISA kit (eBioscience), according to the manufacturer's instructions. For measurement of anti-dsDNA antibodies and ANA, peripheral blood serum samples were collected from all experimental mice and analyzed by commercially available ELISA kits (Alpha Diagnostics) according to the manufacturer's instructions.

### Isolation of mouse BMMSCs.

Single suspension of BM-derived all-nuclear cells (ANCs; 15 × 10^6^) from femurs and tibias was seeded into 100 mm culture dishes (Corning) and cultured at 37°C with 5% CO~2~. After 2 d, nonadherent cells were removed, and attached cells were cultured for 16 d in α-MEM (Invitrogen) supplemented with 20% FBS, 2 mM [l]{.smallcaps}-glutamine (Invitrogen), 55 µM 2-mercaptoethanol (Invitrogen), 100 U/ml penicillin, and 100 µg/ml streptomycin (Invitrogen). These plastic attached single colonies were passaged with frequent medium changes to eliminate potential hematopoietic cells contamination ([@bib57]; [@bib78]). Flow cytometric analysis was performed to show a surface epitope profile of isolated BMMSCs ([Fig. 2 A](#fig2){ref-type="fig"}). To further confirm that the single colony-derived plastic adherent BMMSCs were not contaminated with hematopoietic cells, we depleted T cells in BMMSC culture using CD3 antibody treatment. In brief, 1 ml CD3 antibody was added to 10^7^ BMMSCs and the mixture was incubated at 4°C for 30 min. The cells were centrifuged for 5 min to remove unbound antibody, resuspended in 1 ml diluted (1:6) rabbit complement (Pel-Freez Biologicals) and incubated at 37°C for 30 min. Subsequently, CD3 antibody/complement treatment was repeated once ([@bib19]). In addition, we sorted BMMSCs from BM cells according to their MSC-specific surface markers using flow cytometry, as reported previously ([@bib24]). BM cells were selected by lineage markers (Lin^−^) and then sorted by PDGFRα and Sca-1 (PαS). Alizarin Red staining and Western blot analysis showed that BMMSCs derived from plastic collected single colonies, CD3 antibody/complement depletion, and flow cytometric sorting had similar osteogenic abilities ([Fig. 2, B and C](#fig2){ref-type="fig"}). For CFU-F assay, 10^6^ ANCs from BM were seeded in T25 cell culture flasks (Corning). After 16 d, the cultures were washed by PBS and stained with 1% toluidine blue solution with 2% paraformaldehyde. The cell clusters with more than 50 cells were counted as colonies under microscopy.

### Osteogenic differentiation assay.

BMMSCs were cultured under osteogenic culture condition, containing 2 mM β-glycerophosphate (Sigma-Aldrich), 100 µM [l]{.smallcaps}-ascorbic acid 2-phosphate (Wako), and 10 nM dexamethasone (Sigma-Aldrich) in the growth medium. After 3 wk induction, 1% Alizarin Red S (Sigma-Aldrich) staining was performed to detect matrix mineralization, and the stained areas were quantified by ImageJ software and shown as a percentage of the total area.

### Western immunoblotting.

Cells were lysed in M-PER mammalian protein extraction reagent (Thermo Fisher Scientific) with protease and phosphatase inhibitors (Roche), and proteins were quantified using protein concentration assay (Bio-Rad Laboratories). 20 µg of proteins were separated by SDS-PAGE and transferred to 0.2 µm nitrocellulose membranes (Millipore). The membranes were blocked with 5% nonfat dry milk and 0.1% Tween-20 for 1 h, followed by incubation overnight with the primary antibodies diluted in blocking solution according to manufacturer's instructions. Antibodies to mouse ALP, LPL, PPARγ2, IL4Rα, PI3K-p110, phosphor-SMAD2/3, and SP1 were purchased from Santa Cruz Biotechnology, Inc. Antibodies to human RUNX2, ALP, and OCN were purchased from Santa Cruz Biotechnology, Inc. Antibodies to phosphor-mTOR (Ser2448), mTOR, phospho-Akt (Ser473), Akt, phosphor-P70S6K (T389; S371), phosphor-Rictor, phosphor-Raptor, and SMAD2/3 were obtained from Cell Signaling Technology. Antibodies to mouse RUNX2, FBN1, OCN, and β-actin were purchased from Abcam, GeneTex, Millipore, and Sigma-Aldrich. The membranes were then incubated for 1 h in HRP-conjugated secondary antibody (Santa Cruz Biotechnology, Inc.) diluted at 1:10,000 in blocking solution. Immunoreactive proteins were detected using SuperSignal West Pico Chemiluminescent Substrate (Thermo Fisher Scientific) and BioMax film (Kodak). The intensity of bands was measured by using ImageJ software and normalized to β-actin.

### Adipogenic differentiation.

For adipogenic induction, 500 nM isobutylmethylxanthine (Sigma-Aldrich), 60 µM indomethacin (Sigma-Aldrich), 500 nM hydrocortisone (Sigma-Aldrich), 10 µg/ml insulin (Sigma-Aldrich), and 100 nM [l]{.smallcaps}-ascorbic acid phosphate were added into the growth medium. After 7 d, the cultured cells were stained with Oil red O (Sigma-Aldrich), and positive cells were quantified under microscopy and shown as a number to total cells.

### RNAi and chemical reagent treatments.

BMMSCs (0.5 × 10^6^) were seeded to a 6-well culture plate and treated with *Fbn1* siRNA (Santa Cruz Biotechnology, Inc.), *P70s6k* siRNA (Santa Cruz Biotechnology, Inc.), *Il4rα* shRNA (Santa Cruz Biotechnology, Inc.), or *Mtor* shRNA (Addgene), according to the manufacturers' instructions. After transfection, cells were either used for protein extraction for Western immunoblotting or for differentiation induction. For chemical reagent treatments, serum-starved MSCs were treated with 10--100 ng/ml rIL-4 (R&D Systems), 50 nM rapamycin (LC Laboratories), or 1 µg/ml TGF-β neutralized antibody (R&D Systems). For Western immunoblotting, MSCs were cultured under growth medium with drugs for 24 h, and protein was extracted by using M-PER mammalian protein extraction reagent. For differentiation induction, MSCs were cultured under inductive conditions in the presence of drugs (added every 3 d) for 3 wk, followed by staining and gene expression analysis.

### Flow cytometric analysis of T~H~2 cells.

To detect T~H~2 percentage of CD4^+^ cells in BM and splenocyte ([@bib3]), BM or splenocyte-derived single-suspension ANCs were incubated with anti-CD4-PerCP (BioLegend), followed by staining with anti--IFN-γ-APC (BioLegend) and anti-IL4-PE (eBioscience), anti--IL5-PE (eBioscience), or anti--IL13-eFluor 660 (eBioscience) using an intracellular antigen staining kit (eBioscience). To further identify T~H~2 cells infiltration, ANCs were incubated with anti-CD4-PerCP, followed by staining with combined T~H~2 cytokines, such as anti--IL4-PE/anti--IL13-eFluor 660 and anti--IL5-PE/anti--IL13-eFluor 660 antibodies, using an intracellular antigen staining kit. Because CC-chemokine receptor 3 (CCR3) has been reported as a marker for T~H~2 cells ([@bib52]), we detected CD4^+^CCR3^+^, CD4^+^CCR3^+^IL4^+^, and CD4^+^CCR3^+^IL13^+^ subpopulations using anti-CCR3-FITC antibody (BioLegend). Cells were analyzed by FACS^Calibur^ with CellQuest software (BD).

### Immunofluorescent microscopy.

BMMSCs were cultured on 4-well chamber slides (Nunc; 2 × 10^3^/well) and then fixed with 4% paraformaldehyde. The Chamber slides are incubated with primary anti CD73 antibody (1:400; BD) and anti-IL4Rα (1:400; BD) at 4°C for overnight and then treated with Rhodamine-conjugated secondary antibody (1:400; SouthernBiotech) or Alexa Fluor 488--conjugated secondary antibody (1:200, Invitrogen) for 30 min at room temperature. Finally, slides were mounted with VECTASHIELD mounting medium (Vector Laboratories).

### IL4-treated in vivo BMMSC implantation assay.

BMMSCs were mixed with HA/TCP ceramic powders, and Extracel-HP hydrogel (Glycosan Biosystems), containing 200 ng IL4, was covered on the surface of the implants for slow release of the cytokine ([@bib39]). At 8 wk after implantation, the implants were harvested and decalcified. Newly formed mineralized tissue areas were analyzed by paraffin section and H&E staining.

### Luciferase reporter assay.

Promoter reporters were prepared as our previous description ([@bib8]). *Il4rα*-luciferase promoter reporter constructs were generated by PCR using Pfu polymerase and mouse genomic DNA as a template. Primers containing upstream XhoI and HindIII downstream restriction sites were used to generate *Il4r*α promoter fragment (forward, 5′-CTCGAGGAATTCATGCTGCTTTCTCG-3′, and reverse, 5′-AAGCTTGGCTTTCCCACCGCCCGTT-3′). Restriction-digested PCR products were subcloned into pGL3-Basic vector (Promega). Point mutants were introduced into the reporter by the Pfu--DpnI method. All clones were confirmed by sequencing on both strands. BMMSCs cultured in 6-well plates were cotransfected with 2 µg of luciferase reporter and 100 ng Renilla luciferase expression vector to control for transfection efficiency. 48 h after transfection, cells were lysed in 1× passive lysis buffer, and luciferase activity was measured using the Dual-Glo Luciferase System (Promega) and a luminometer (Turner Biosystems).

### ChIP assays.

BMMSCs grown in 10-cm cell culture dishes were fixed for 10 min at room temperature by addition of 1% paraformaldehyde to the growth medium. Cells were washed twice in cold PBS supplemented with complete protease inhibitor cocktail and gently scraped from the plate. Cell lysis and ChIP were performed using the ChIP Assay kit (Millipore). For chromatin fragmentation, cells were sonicated using a Branson Sonifier 450 on power setting 4 in 30-s bursts with 1 min cooling on ice for a total sonication time of 4 min. For immunoprecipitations, 1:100 dilution of SP1 antibody was used to capture protein--DNA complexes, and isotype-matched IgG was used as negative control. All resulting precipitated DNA samples were quantified with real-time PCR and expressed as the percentage of input DNA.

### Statistics.

All experimental group sizes were chosen to ensure adequate statistical power despite the highly variable nature of the studies performed. No animal excluded, and animals were randomly assigned groups for the studies. All experiments were not performed in a blinded fashion. Data were assessed for normal distribution and similar variance between groups. Comparisons between two groups were analyzed by independent unpaired two-tailed Student's *t* test, and the comparisons between more than two groups were analyzed by one-way ANOVA with the Bonferroni adjustment. The p-values \<0.05 were considered statistically significant.
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